AtriCure Q2 revenue $71.4M (+74.8% YoY); aMAZE trial fails efficacy endpoint

AtriCure, Inc.

Revenue $71.4M, up 74.8% YoY (73.5% constant currency); U.S. $60.1M (+78.4%), international $11.3M (+57.9%).
Net loss per share $0.36; adjusted loss per share $0.30; adjusted EBITDA loss $2.7M.
FY2021 revenue guidance raised to $270-275M (growth ~31-33%); adjusted loss per share guidance ~$1.20.
aMAZE trial failed primary efficacy endpoint; safety endpoint met. Potential material adjustments expected in H2 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.